Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.37 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285928 | 0.93 | KMT2A (0.39) | F3KMT2AMEN1MAPK1POLB | |
| SCHEMBL6286360 | 0.90 | ACLY (0.38) | KMT2AMEN1ALOX15ACLYNPSR1 | |
| SCHEMBL6496749 | 0.87 | ALOX15 (0.48) | KMT2AMEN1POLBSMN1; SMN2TDP1 | |
| SCHEMBL6288186 | 0.86 | IRAK4 (0.38) | KMT2AMEN1MAPK1POLBACLY | |
| SCHEMBL6279221 | 0.85 | RIPK1 (0.52) | MAPK1 | |
| SCHEMBL6285019 | 0.84 | ACLY (0.36) | KMT2AMEN1MAPK1POLBTDP1 | |
| SCHEMBL6504814 | 0.84 | ACLY (0.38) | KMT2AMEN1ALOX15ACLYNPSR1 | |
| SCHEMBL6288131 | 0.83 | IRAK4 (0.40) | KMT2AMEN1MAPK1POLBSMN1; SMN2 | |
| SCHEMBL6286030 | 0.83 | ALDH1A1 (0.53) | KMT2AMEN1SMN1; SMN2TDP1NPSR1 | |
| SCHEMBL6288150 | 0.83 | ACLY (0.37) | KMT2AMEN1MAPK1POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943174-B2 | 6,5-Fused bicyclic heterocycles | WARNER-LAMBERT COMPANY (US) | 2005-09-13 | — | — | US | claimed |
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | claimed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6943174-B2 | 6,5-Fused bicyclic heterocycles | WARNER-LAMBERT COMPANY (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | ALOX15, ALOX5, ALOX15B | F3 488/4885KMT2A 4200/4885MEN1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.